Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 35-4 - July 15, 2021
- Latest edition
- Editor: Jennifer R. Brown︎
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 9 6 9 2 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 9 6 9 3 - 1
This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our se… Read more
Purchase options
This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia
Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic LeukemiaThe Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical ImplicationsPrognostic and Predictive Implications of Cytogenetics and GenomicsGenomics of Resistance to Targeted TherapiesFirst-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and BeyondBruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond IbrutinibShould Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton’s Tyrosine Kinase InhibitorsThe Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaCan Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond
- Edition: 1
- Latest edition
- Volume: 35-4
- Published: July 15, 2021
- Language: English
JB
Jennifer R. Brown︎
Affiliations and expertise
Professor of Medicine, Harvard Medical School,Director of CLL Center, Dana-Farber Cancer Institute, USA